• Curium’s strategic investment of over €32 million will establish a European production line for ¹⁷⁷Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer
• This investment positions France at the forefront of this innovative cancer treatment technology and is part of broader industrial commitments in France, covering European demand for targeted prostate cancer therapy

PARIS, June 01, 2026 (GLOBE NEWSWIRE) — Curium, a global leader in nuclear medicine, today announced at the Choose France summit in Versailles, a major industrial investment program in France to the value of €32 million. This investment will strengthen its production capabilities for radiopharmaceuticals through the…